Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.

Lilly Endowment Inc. sold a significant number of Eli Lilly & Co. shares on June 10, 2024, reducing its holdings.

Summary

• Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a total of 62,800 shares of common stock on June 10, 2024.
• The sales were executed in multiple transactions at varying prices, ranging from $851.19 to $870.74 per share.
• The weighted average prices for each block of shares sold are detailed in the document.
• Following these transactions, Lilly Endowment Inc.'s direct holdings in Eli Lilly & Co. decreased to 97,793,810 shares.

Sentiment

Score: 5

Explanation: The document is a neutral report of a share sale, with no indication of positive or negative sentiment towards the company's performance or future prospects.

Industry Context

This filing is a routine disclosure of a significant shareholder's transactions and does not necessarily indicate a change in the company's fundamentals or outlook. It is common for large institutional investors to adjust their holdings periodically.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and large shareholders in publicly traded companies.
• The level of detail provided, including the range of prices and weighted average prices, is consistent with SEC requirements for these filings.
• Similar filings are made by other large institutional investors in pharmaceutical companies such as BlackRock, Vanguard, and State Street, when they adjust their holdings.

Stakeholder Impact

• The share sale may have a minor impact on the stock price, but it is unlikely to significantly affect the company's operations or long-term prospects.
• Shareholders may be interested in the transaction as it provides insight into the actions of a major investor.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, SEC Form 4